Literature DB >> 16235241

Statistical dissection of genetic pathways involved in prostate carcinogenesis.

Franclim R Ribeiro1, Chieu B Diep, Carmen Jerónimo, Rui Henrique, Carlos Lopes, Mette Eknaes, Ole Christian Lingjaerde, Ragnhild A Lothe, Manuel R Teixeira.   

Abstract

Molecular markers that could stratify prostate cancer patients according to risk of disease progression would allow a significant improvement in the management of this clinically heterogeneous disease. In the present study, we analyzed the genetic profile of a consecutive series of 51 clinically confined prostate carcinomas and 27 benign prostatic hyperplasias using comparative genomic hybridization (CGH). We then added our findings to the existing literature data in order to perform a meta-analysis on a total of 294 prostate cancers with detailed CGH and clinicopathological information, using multivariate statistical methods that included principal component, hierarchical clustering, time of occurrence, and regression analyses. Whereas several genomic imbalances were shared by organ-confined, locally invasive, and metastatic prostate cancers, 6q and 10q losses and 7q and 8q gains were significantly more frequent in patients with extra-prostatic disease. Regression analysis indicated that 8q gain and 13q loss were the best predictors of locally invasive disease, whereas 8q gain and 6q and 10q losses were associated with metastatic disease. We propose a genetic pathway of prostate carcinogenesis with two distinct initiating events, namely, 8p and 13q losses. These primary imbalances are then preferentially followed by 8q gain and 6q, 16q, and 18q losses, which in turn are followed by a set of late events that make recurrent and metastatic prostate cancers genetically more complex. We conclude that significant differences exist in the genetic profile of organ-confined, locally invasive, and advanced prostate cancer and that genetic features may carry prognostic information independently of Gleason grade.

Entities:  

Mesh:

Year:  2006        PMID: 16235241     DOI: 10.1002/gcc.20279

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  12 in total

1.  TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.

Authors:  Nuno Cerveira; Franclim R Ribeiro; Ana Peixoto; Vera Costa; Rui Henrique; Carmen Jerónimo; Manuel R Teixeira
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

2.  Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions.

Authors:  Kosuke Miyai; Mukul K Divatia; Steven S Shen; Brian J Miles; Alberto G Ayala; Jae Y Ro
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

3.  Genomic aberrations in borderline ovarian tumors.

Authors:  Francesca Micci; Lisbeth Haugom; Terje Ahlquist; Hege K Andersen; Vera M Abeler; Ben Davidson; Claes G Trope; Ragnhild A Lothe; Sverre Heim
Journal:  J Transl Med       Date:  2010-02-26       Impact factor: 5.531

4.  Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas.

Authors:  Franclim R Ribeiro; Rui Henrique; Merete Hektoen; Marianne Berg; Carmen Jerónimo; Manuel R Teixeira; Ragnhild A Lothe
Journal:  Mol Cancer       Date:  2006-09-04       Impact factor: 27.401

5.  Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array.

Authors:  N Tørring; M Borre; K D Sørensen; C L Andersen; C Wiuf; T F Ørntoft
Journal:  Br J Cancer       Date:  2007-01-23       Impact factor: 7.640

6.  Tumor spreading to the contralateral ovary in bilateral ovarian carcinoma is a late event in clonal evolution.

Authors:  Francesca Micci; Lisbeth Haugom; Terje Ahlquist; Vera M Abeler; Claes G Trope; Ragnhild A Lothe; Sverre Heim
Journal:  J Oncol       Date:  2009-09-15       Impact factor: 4.375

Review 7.  [TMPRSS2-ETS gene fusion in prostate cancer].

Authors:  S Perner; F H Schmidt; M D Hofer; R Kuefer; M Rubin
Journal:  Urologe A       Date:  2007-07       Impact factor: 0.803

Review 8.  Current perspectives in the treatment of advanced prostate cancer.

Authors:  Victor Valdespino; Panagiotis Tsagozis; Pavel Pisa
Journal:  Med Oncol       Date:  2007       Impact factor: 3.738

9.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.

Authors:  M Yoshimoto; I W Cunha; R A Coudry; F P Fonseca; C H Torres; F A Soares; J A Squire
Journal:  Br J Cancer       Date:  2007-08-14       Impact factor: 7.640

10.  Genome-wide investigation of multifocal and unifocal prostate cancer-are they genetically different?

Authors:  Chinyere Ibeawuchi; Hartmut Schmidt; Reinhard Voss; Ulf Titze; Mahmoud Abbas; Joerg Neumann; Elke Eltze; Agnes Marije Hoogland; Guido Jenster; Burkhard Brandt; Axel Semjonow
Journal:  Int J Mol Sci       Date:  2013-06-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.